Sustained Improvements in Clinical and Patient-Reported Outcomes and Quality of Life Through 5 Years Among Ixekizumab-Treated Patients with Complete Clearance of Scalp Psoriasis by Week 60

By sjmartinez • April 23, 2024

Egeberg A, Hawkes JE, Somani N, Burge R, See K, Gallo G, McKean-Matthews M, Gooderham M, Han G, Armstrong A. Sustained Improvements in Clinical and Patient-Reported Outcomes and Quality of Life Through 5 Years Among Ixekizumab-Treated Patients with Complete Clearance of Scalp Psoriasis by Week 60. Dermatol Ther (Heidelb). 2024 Apr 22. doi: 10.1007/s13555-024-01147-7. Epub ahead of print. PMID: 38647975.

Tags: Clinical outcomes, Dermatology, ixekizumab, long-term, patient-reported outcomes, psoriasis, Publications, Quality of Life, Scalp clearance

Do female patients see their physicians differently? A population-based study evaluating perception of physician communication by patients with hidradenitis suppurativa

Harvey LF, Kingston P, Kikuchi R, Manasyan A, Sadrolashrafi K, Hao A, Tolson H, Yee D, Armstrong AW. Do female patients see their physicians differently?[...]

Defining On-Treatment Remission in Plaque Psoriasis: A Consensus Statement From the National Psoriasis Foundation

Armstrong AW, Gondo GC, Merola JF, Roberts AM, Pérez-Chada LM, Balak DMW, Eakin GS, Read C, Le ST, Gutierrez Y, Bhutani T, Blauvelt A, Duffin[...]

Scarring alopecia as an unexpected consequence of immune checkpoint inhibition

Kokikian N, Tarabay J, Goh C. Scarring alopecia as an unexpected consequence of immune checkpoint inhibition. JAAD Case Rep. 2025 May 8;61:1-6. doi: 10.1016/j.jdcr.2025.04.007. PMID:[...]